Aptevo Therapeutics Inc APVO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Aptevo Advances Next-Generation Trispecific Candidate Toward Clinical Development
-
Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML
-
Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results
-
Aptevo Therapeutics Announces Closing of Existing Warrants Exercise and PIPE for $4.5 Million Gross Proceeds
-
Aptevo Therapeutics Announces Exercise of Existing Warrants and PIPE for $4.5 Million Gross Proceeds
-
Aptevo Strengthens Solid Tumor Strategy with Patent Filing for Nectin-4 x PD-L1 Dual Targeting Backbone
Trading Information
- Previous Close Price
- $1.76
- Day Range
- $1.76–1.80
- 52-Week Range
- $1.37–35.64
- Bid/Ask
- $1.72 / $1.86
- Shares Outstanding
- 1.81M
- Market Cap
- $3.19M
- Volume/Avg
- 82 / 110,221
Key Statistics
- Price/Earnings (Normalized)
- 0.03
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, CD3xCD123, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 33
Valuation
|
Metric
|
APVO
|
|---|---|
Price/Earnings (Normalized) | 0.03 |
Price/Book Value | 0.41 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
APVO
Financial Strength
|
Metric
|
APVO
|
|---|---|
Quick Ratio | 1.89 |
Current Ratio | 2.08 |
Interest Coverage | — |
Quick Ratio
APVO
Profitability
|
Metric
|
APVO
|
|---|---|
Return on Assets (Normalized) | −125.74% |
Return on Equity (Normalized) | −222.34% |
Return on Invested Capital (Normalized) | −163.00% |
Return on Assets
APVO
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|PJPR#!% | LOCK|Y<Nkp | $128B | |||
| Moderna Inc
MRNA
| LOCK|Y>$z#g | LOCK|t^B | $76B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|j$?ghDL | LOCK|DZ$#V | $76B | |||
| argenx SE ADR
ARGX
| LOCK|<brJMs& | LOCK|M$$ | $57B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|@pSDT&c | LOCK|?> | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|@Sy<xp@ | LOCK|@^Jn@ | $29B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|dZchgZd | LOCK|?hrJ | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|>hBw<w | LOCK|vn< | $24B | |||
| Incyte Corp
INCY
| LOCK|SnsSdY | LOCK|wl | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|Z#K?#qy | LOCK|VyG | $15B |
United States